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Abstract
Knowledge of an individual’s human leukocyte antigen (HLA) genotype is essential
for modern medical genetics, and is crucial for hematopoietic stem cell and solid-
organ transplantation. However, the high levels of polymorphism known for the HLA
genes make it difficult to generate an HLA genotype that unambiguously identifies
the alleles that are present at a given HLA locus in an individual. For the last
20 years, the histocompatibility and immunogenetics community has recorded this
HLA genotyping ambiguity using allele codes developed by the National Marrow
Donor Program (NMDP). While these allele codes may have been effective for
recording an HLA genotyping result when initially developed, their use today results
in increased ambiguity in an HLA genotype, and they are no longer suitable in the era
of rapid allele discovery and ultra-high allele polymorphism. Here, we present a text
string format capable of fully representing HLA genotyping results. This Genotype
List (GL) String format is an extension of a proposed standard for reporting killer-
cell immunoglobulin-like receptor (KIR) genotype data that can be applied to any
genetic data that use a standard nomenclature for identifying variants. The GL String
format uses a hierarchical set of operators to describe the relationships between
alleles, lists of possible alleles, phased alleles, genotypes, lists of possible genotypes,
and multilocus unphased genotypes, without losing typing information or increasing
typing ambiguity. When used in concert with appropriate tools to create, exchange,
and parse these strings, we anticipate that GL Strings will replace NMDP allele codes
for reporting HLA genotypes.
Introduction
The human leukocyte antigen (HLA) genes on human chromo-
some 6p21 are the most polymorphic and medically relevant
genes in the human genome (1–4). In April 2013, 9106 dis-
tinct nucleotide sequences at 19 HLA genes were known
to encode 6617 unique HLA proteins (5). These HLA pro-
teins are cell-surface antigens that present endogenously and
exogenously derived 8–10 residue peptides for inspection by
T cells, permitting the discrimination of self from nonself
by the adaptive immune system (6, 7). In addition, class I
HLA proteins (which present endogenous peptides) serve as
ligands for killer-cell immunoglobulin-like receptors (KIR),
which regulate cell killing and cytokine response as part of
the innate immune system (8, 9).
The high diversity of HLA proteins is driven by their
peptide binding function; each protein can present a small
population of chemically similar peptides, which are bound
by a peptide binding groove formed by a few dozen amino
acid residues (6, 10, 11). These residues are encoded by exons
2 and 3 of the class I HLA genes (e.g. HLA-A, -B, -C, -E,
-F, and -G) and by exon 2 of the class II HLA genes (DRA,
DRB1, DRB3, DRB4, DRB5, DQA1, DQB1, DPA1, DPB1,
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DMA, DMB, DOA, and DOB) (12–14). Evolutionary mech-
anisms (e.g. host–pathogen coevolution) have generated a
broad diversity of peptide binding groove chemistries by shuf-
fling sets of amino-acid residues between proteins, and selec-
tion for the ability to present highly immunogenic peptides
has resulted in extensive linkage disequilibrium (LD) between
the individual nucleotide polymorphisms in an HLA gene
(15–20). Each such set of polymorphisms in LD is known as
an HLA allele, and the World Health Organization Nomen-
clature Committee for Factors of the HLA System (HLA
Nomenclature Committee) maintains a system of allele names
that describes the sequence relationships between alleles in a
hierarchical fashion (14). Each allele name consists of a set
of 2–4 fields that numerically identify distinct allele families,
unique protein sequences, silent-substitutions, and noncoding
substitutions. The name of each recognized HLA allele and its
associated nucleotide and peptide sequence is curated in the
IMGT/HLA Database (www.ebi.ac.uk/ipd/imgt/hla/). Since
1987 (21), when only 19 distinct HLA alleles were recognized,
the number of alleles has increased regularly and significantly,
with growth driven by the advent of new technologies for
investigating nucleotide sequence diversity (5).
Given these key roles played by HLA in the innate and
adaptive immunity it is not surprising that many individ-
ual HLA alleles confer susceptibility to and protection
from infectious and autoimmune diseases, pharmacological
sensitivities, and cancers. More than 100 such disease-
phenotype associations are known (3), and more than 1000
disease-associated HLA single-nucleotide polymorphisms
(SNPs) have been identified (4). Further, the outcome of
a hematopoietic stem cell (HSC) or solid-organ transplant
is dependent on the degree to which the HLA alleles of
patients and donors are ‘matched’; HSC transplant outcome
is significantly improved for HLA-identical donor–patient
pairs over ‘mismatched’ donor–patient pairs, where even a
single HLA allele differs between donor and patient (22).
HLA genotyping and ambiguity
Knowledge of an individual’s HLA genotype is therefore
crucial in the age of personalized genomic medicine. Ideally,
knowledge of the complete nucleotide sequences of a patient’s
HLA genes would allow deep insight into their immune
function and medical predisposition. However, the extensive
polymorphism at both the nucleotide and allele levels among
the HLA genes has made HLA genotyping complicated, and
the ideal of certain knowledge of an individual’s HLA alleles
remains a distant goal. HLA nucleotide polymorphisms are
often not simple biallelic SNPs; in many cases, all four
nucleotide residues exist as variants of a given position,
and multiple adjacent nucleotide positions (e.g. multiple
codons) may be polymorphic. HLA polymorphism must
often be assessed across multiple exons, and HLA genes
are themselves homologous, making it difficult to assign
nucleotide sequences to a particular gene.
Given these challenges, multiple polymerase chain reac-
tion (PCR)-based techniques have been developed for
HLA genotyping; the most commonly used of these are
hybridization-based sequence-specific priming (SSP) and
sequence-specific oligonucleotide (SSO) probe methods, and
sequence-based typing (SBT) methods (23). While each
method uses different approaches to assess the relevant poly-
morphisms necessary to identify an HLA allele, all are limited
in the region of each gene that can be assessed, and in their
ability to establish phase between assessed regions. These
limitations can result in ambiguity – uncertainty in a genotyp-
ing result such that a method cannot identify exactly two HLA
alleles for a given locus. In general, HLA genotyping results
display two discrete categories of genotyping ambiguity.
Allelic ambiguity results when not all relevant nucleotide
positions are interrogated; this type of ambiguity occurs
with SSO and SSP methods when polymorphisms are
located between probe or primer regions or when probes or
primers cannot detect a variant, and with SBT methods when
polymorphisms occur outside the region that was sequenced.
For example, the HLA-A*02:03:01 , HLA-A*02:253 , HLA-
A*02:264 , and HLA-A*02:370 alleles share identical exon
2 and 3 nucleotide sequences; these alleles will constitute
an ambiguous allele set when typed using an SBT method
that interrogates only HLA-A exons 2 and 3. The HLA
Nomenclature Committee has developed a nomenclature
for describing HLA class I alleles that share identical exon
2 and 3 sequences, and HLA class II alleles that share
identical exon 2 sequences. All such alleles are assigned to
a ‘G group’ named using the first three fields of the lowest-
numbered allele in that ambiguous allele set, followed by the
letter G (14). Thus the HLA-A*02:03:01 , HLA-A*02:253 ,
HLA-A*02:264 , and HLA-A*02:370 alleles are all part of
the HLA-A*02:03:01G group. This G group nomenclature
is useful for representing ambiguous alleles generated via
SBT methods, but SSO methods may not have the capacity
to assess all polymorphisms in the relevant exons, and may
therefore generate even more ambiguous results.
Genotypic ambiguity results when chromosomal phase
cannot be established between polymorphisms; this type of
ambiguity also occurs with SSP, SSO, and SBT methods.
For example, the ‘HLA-A*01:01:03 and HLA-A*02:01:04 ’
and ‘HLA-A*01:01:01 and HLA-A*02:01:18 ’ genotypes
are consistent with the same set of diploid exon 2 and
3 nucleotide sequences, and will constitute an ambiguous
genotype combination when typed using an SBT method that
does not establish phase between HLA-A exons 2 and 3 (24).
The extent of allelic and genotypic ambiguity can be
large in some common HLA genotypes. For example, in
release 3.9.0 of the IMGT/HLA Database (5), the ambiguous
genotype combinations that correspond to the four exon 2 and
3 nucleotide sequences represented by the HLA-A*02:01:01G
and HLA-A*03:01:01G G groups include 555 genotypes
when these G groups are expanded to their constituent alleles.
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The number of genotype combinations in this case can be
considerably higher when an SSOP or SSP method is used
rather than an SBT method.
Finally, the regular identification of new HLA alleles
has made the consistent management of HLA genotype
data challenging. An HLA genotyping result that may be
unambiguous at one point in time may become ambiguous at
a later date, when a new nucleotide variation is reported that
was not excluded at the time of the original typing.
Recording genotyping ambiguity
Historically, there has been a lack of consensus with respect to
the recording of allelic and genotypic ambiguities. The HLA
Nomenclature Committee recommends the use of the forward
slash (/) and comma (,) as operators for reporting allele
ambiguity (e.g. the above-mentioned ambiguous allele set
can be recorded as HLA-A*02:03:01/02:253/02:264/02:370 ,
which is generally referred to as an ‘allele string’) and
distinguishing the diploid alleles at a locus (e.g. the above-
mentioned genotypes can be recorded as HLA-A*01:01:03,
02:01:04 and HLA-A*01:01:01, 02:01:18 ), but there is no
standard method for recording ambiguous genotype combina-
tions. In particular when ambiguity is extensive, laboratories
often only report the lowest-numbered allele pair; this is a
dangerous simplification that contradicts most standards.
The most commonly used approach for reporting and
transmitting ambiguous HLA genotype data has been to
use the allele code system developed by the NMDP. This
system replaces the 2nd–4th fields of an allele name with
a 2–5 letter code that represents an allelic ambiguity string.
For example, the ambiguous HLA-A*01:01/01:02 , HLA-
A*02:01/02:24/02:101 genotype is coded as HLA-A*01:AB ,
HLA-A*02:CVEG . When NMDP allele codes were first
introduced in the 1990s, only a few hundred HLA alleles had
been identified and it was assumed that only a small number
of alleles remained to be identified. Since then, the number
of allele codes has grown extremely large in response to
the growth in number of HLA alleles. As of March 2013,
200,047 distinct allele codes have been assigned. Applied to
multiple allele-families across the HLA loci, several million
unique allele codes can be generated.
While use of allele codes is preferable to the simple
truncation of the allele string, in that it allows more complete
recording and transmission of a genotyping result, the NMDP
allele code system remains an imperfect method of recording
and transmitting modern HLA genotype data for the reasons
that follow.
Limitations of allele codes
Inability to encode genotype ambiguity
The NMDP allele code system cannot encode genotypic
ambiguity. Genotypic ambiguity must be ‘compressed’ into
allelic ambiguity before a typing can be encoded. There-
fore, any phase information in the genotyping result can-
not be represented in the allele code and is lost in the
encoding process. For example, a typing result of two pos-
sible genotypes of HLA-A*02:01 , HLA-A*11:08 or HLA-
A*02:02 , HLA-A*11:20 will be reported as HLA-A*02:AB ,
HLA-A*11:HNF , which expands into the following four
possible genotypes: HLA-A*02:01 , HLA-A*11:08 or HLA-
A*02:02 , HLA-A*11:20 or HLA-A*02:01 , HLA-A*11:20 or
HLA-A*02:02 , HLA-A*11:08 .
When genotypic ambiguities are converted to allele codes,
new genotypes not included in the original genotyping result
are introduced, and phase information for that locus is
completely lost.
Outmoded assumptions about HLA polymorphism
The NMDP allele code system generally assumes that
most ambiguity will pertain to the 2nd field of an allele
name. Ambiguities that pertain to the 3rd and 4th fields
of allele names cannot be recorded, because allele codes
only represent amino acid sequences. For example, the
HLA-A*02:01:05/02:02:02 ambiguity is shortened to
HLA-A*02:01/02:02 prior to encoding, and is coded as
HLA-A*02:AB . A different allelic ambiguity (e.g. HLA-
A*02:01:04/02:02:01 ) is also encoded to HLA-A*02:AB . An
ambiguity derived from synonymous substitutions, such as
HLA-A*02:01:06/02:01:07 , cannot be encoded. Therefore,
when genotyping results are converted to allele codes, new
ambiguity is introduced and information in the 3rd and 4th
fields of allele names is lost.
In addition, the NMDP allele code system generally
assumes that there will be no ambiguity in the 1st field of allele
names. With the exception of the DPB1 locus, the 1st field of
an allele name represents a specific ‘allele family’ at a given
locus. These allele families have historically corresponded
to specific immunogenic peptide domains, and were origi-
nally defined via serological typing. However, as the number
of known alleles has increased, alleles that cannot easily be
assigned to a specific allele family on the basis of nucleotide
sequence have been identified. As a consequence of these
serologically uncertain alleles and the patchwork structure of
the HLA polymorphism, an increasing number of genotyping
results now include ambiguities involving the 1st field. This
leads to a growing numbers of allele codes crossing those
generic groups.
NMDP allele codes cannot be generally applied to alleles
that are in different allele families. For example, an ambigu-
ous typing result of HLA-A*02:03:01/02:253/23:17 cannot
be converted to an allele code. Although some specific
cross-family allele codes have been created (e.g. the HLA-
DRB1*13:DJ code represents the HLA-DRB1*13:01/13:02/
13:04/13:05/13:06/13:07/14:09 allelic ambiguity), allele
codes that specifically incorporate ambiguities in the first
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Table 1 Genotype List String data format definition and precedence
Precedencea Delimiter Description Example
5 / Allele ambiguity HLA-A*02:01/HLA-A*02:02
4 ∼ Phased genes HLA-DRB3*01:01∼HLA-DRB1*03:01
3 + Copies of genes HLA-A*02:01/HLA-A*02:02+HLA-A*03:01
2 | Genotype ambiguity HLA-A*02:01/HLA-A*02:02+HLA-A*03:01|HLA-A*02:07+HLA-A*03:06
1 ˆ Genes HLA-A*02:01/HLA-A*02:02+HLA-A*03:01|HLA-A*02:07+HLA-A*03:06ˆ
HLA-B*08:01+HLA-B*44:02/HLA-B*44:03
aPrecedence is evaluated in the numerical order shown.
Figure 1 Genotype List (GL) String representation of a multilocus unphased genotype. A GL String representing HLA-A genotype (A*02:69 and
A*23:30, or A*02:302 and, either A*23:26 or A*23:39) and HLA-B genotype (B*44:02:13 and B*49:08) for a single individual is shown. GL String
delimiters are parsed hierarchically starting from the locus delimiter (ˆ), proceeding to the genotype delimiter (|), then the chromosome delimiter (+),
and ending with the allele delimiter (/).
field of allele names are primarily used only for the DPB1
locus (for which the concept of an allele family does not
apply). Because the NMDP allele code system cannot easily
accommodate ambiguities in the 1st field, additional HLA
typing is often used to exclude these ambiguities, increasing
the cost and time required to report a genotype.
Allele code management bottlenecks
New NMDP allele codes are generated and managed in a
nonautomated fashion. With each release of an update from
the HLA Nomenclature Committee, the overall number of
alleles increases. As genotyping efforts are extended to exons
that have not previously been examined, new polymorphisms
are found in what were thought to be well-characterized
alleles. As a result, ambiguity increases with each new
release of the IMGT/HLA Database, and hence a previously
unambiguous genotype can later become ambiguous. If an
NMDP allele code corresponding to an ambiguity does not
exist, or has not been activated for use at a particular locus,
the creation of a new code, or the activation of an existing
code at a new locus, must be requested. This constitutes a rate-
limiting step so far as the efficient recording and transmission
of HLA genotype data goes.
These issues have resulted in recommendations that NMDP
allele codes not be used in HLA reports (24–26) but so far
no specific alternatives have been provided. Other machine-
readable formats have been developed but these require
specific programming skill to use (27). Here, we describe
Genotype List (GL) Strings, a machine-readable and human
intelligible syntax for reporting HLA genotype results that
allows the accurate recording of allele and genotype ambigu-
ity, as well as the integration HLA genotyping results with
data from other genetic systems.
Methods and results
A GL String is a collection of alleles parsed with character
delimiters that organize the alleles in terms of loci, alleles,
lists of possible alleles, phased genes, genotypes, and lists of
possible genotypes. These delimiters, their meaning and the
precedence in which they must be applied are presented in
Table 1. An example GL String is illustrated in Figure 1. A
reduced set of these delimiters was previously proposed for
reporting KIR genotype data (28). The delimiters are described
in greater detail below, in order of decreasing precedence.
Ambiguous alleles
The forward slash character (/) is used to separate possible
alleles in a list. For example, HLA-A*02:01/HLA-A*02:02
denotes two possible alleles. This delimiter has been in
common use among HLA researchers and has been previously
recommended by the HLA Nomenclature Committee for
reporting an ambiguous string of alleles (14).
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Phased genes
The tilde character (∼) is used to separate alleles that
are found on the same chromosome and is used to group
alleles within the same haplotype (cis). For example, HLA-
DRB3*01:01∼HLA-DRB1*03:01 describes two HLA-DRB
alleles that have been identified as being on the same
chromosome.
Copies of genes
The plus character (+) separates alleles that are detected,
but not identified as being on the same chromosome. In
HLA genotypes, this character is most often used to denote
genotypes at a locus, with the alleles found on different
chromosomes (trans). However, it can also be used to denote
copies of genes where chromosomal phase is unknown. For
example, it has been used to represent more than two copies
of a gene in reporting KIR genotype data (28).
Ambiguous genotypes
The pipe character (|) is used to separate possible genotypes
in a list. For example, HLA-A*02:02+HLA-A*03:01|HLA-
A*02:07+HLA-A*03:06 denotes two possible genotypes for
HLA-A.
Genes/loci
The caret character (ˆ) is used to separate loci and is used
to describe multilocus unphased genotypes. For example,
HLA-A*02:01+HLA-A*03:01ˆHLA-B*08:01+HLA-B*44:02
describes two genotypes, one each for the HLA-A and
HLA-B loci.
Other than these five delimiters (/, ∼, +, |, and ˆ) and
appropriate allele identifiers, no additional characters should
be included in GL Strings. For example, white spaces and
tabs must be excluded from GL Strings. We recommend that
HLA allele names in GL Strings be strictly consistent with the
IMGT/HLA Database and always be prefaced with ‘HLA-’ to
explicitly identify HLA data, and that they always include
the full locus name (e.g. A, DRB1, etc.), the asterisk (*)
separator, and the allele designation. For example, the follow-
ing ambiguous HLA-A allele pair should always be written
as HLA-A*01:01:01:01/HLA-A*02:01:01:02L, and never as
HLA-A*01:01:01:01/02:01:01:02L.
The order of delimited elements in a GL String does not
provide any additional meaning for parsing that string. For
example, the order of slash-delimited alleles or pipe-delimited
genotypes does not indicate any greater likelihood of one
allele or one genotype over another. Similarly, the order
of loci in a GL String does not need to correspond to the
relative chromosomal position of those loci. Neither is there
any meaning from order of loci in a GL String with regard to
relative chromosomal position.
The pertinent IMGT/HLA Database release version of
a given allele is not included in a GL String. It is the
responsibility of the creator of the string or the tool generating
the string to convey the IMGT/HLA Database version and
associated metadata to the recipient of the GL String.
Genotype data for any genetic systems that use a standard
nomenclature for identifying polymorphisms can be repre-
sented with GL Strings so long as that nomenclature of the
genetic system does not make use of the GL String delimiters.
For example, genotype data for multiple KIR loci for a single
individual could be represented in a single GL String, as:
KIR2DL1*001 + KIR2DL1*001ˆKIR2DL2*0010101 + KIR2D
L2*0030101ˆKIR2DL5A*0010101+ KIR2DL5A*014ˆKIR2D
L5B*020101 + KIR2DL5B*003ˆKIR2DS3*00101 + KIR2DS
3*0020101ˆKIR2DS4*0010101 + KIR2DS4*002|KIR2DS
4*0040101 + KIR2DS4*0060102ˆKIR2DS5*003/KIR2DS5*
004/KIR2DS5*005 + KIR2DS*001 .
Discussion
We have developed a string format that can fully describe
HLA genotyping results. By applying character delimiters
with defined precedence, GL Strings can be used to record
allele and genotype ambiguity in a standard manner that
does not increase ambiguity or lose information. The adop-
tion of this format as a standard means for recording HLA
genotype data could have widespread ramifications for basic
and clinical research in the fields of histocompatibility and
immunogenetics. A key obstacle to consistency and repro-
ducibility of immunogenomic studies has been the inability to
determine the extent to which genotype data generated by dif-
ferent research groups, using different methodologies and plat-
forms, and at different times represent equivalent results (24).
The ability to store and exchange HLA genotyping results
that accurately represent allelic and genotypic ambiguity will
potentially overcome this obstacle, facilitating the synthesis
of data across platforms, research groups, and nomenclature
epochs.
The GL String format can also be used for other genetic
systems with defined nomenclatures (e.g. KIR) as long as
those nomenclatures do not use the GL String character
delimiters. This flexibility allows data for multiple genetic
systems to be associated in ways that are not currently
possible. For example, it is possible to incorporate HLA and
KIR data for a given individual in the same GL String.
However, we discourage the combination of genotype data
using multiple nomenclatures (or multiple versions of the
same nomenclature) in a single GL String, as the GL String
format does not associate specific nomenclatures with the
individual elements of a GL String.
Other formats
The need to accurately record allele variation is not unique
to HLA research. An understanding of sequence variation is
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foundational to the promise of personalized genomics, and
several different genomic data formats have been described.
Reese et al. have described a Genome Variation Format
(GVF) that is a type of Generic Feature Format (GFF) to
be used with the 10Gen dataset (29). For the 1000 Genomes
project, a Variant Call Format (VCF) (30) consisting of a
text file containing metadata lines, a header line, and data
lines containing positional information has been developed.
These genomic formats are not applicable for nomenclature
systems, as they represent variation presented in the context
of a reference genome.
Managing and using GL Strings
An important goal in the development of GL Strings was to
separate the encoding of genotype data from the management
and presentation of those data. Despite their shortcomings,
NMDP allele codes have been popular because they compress
information into a small amount of printable real estate and
can be easily exchanged using paper records. However, as
discussed above this compression greatly reduces the utility
of HLA genotype data, and the management and maintenance
of allele codes is time-consuming.
As with allele codes, GL Strings have the potential to
become quite numerous and difficult to read. However, they
are easily generated and parsed by computers and the work of
creating and displaying them should be left to machines. The
remaining challenge is one of exchanging the strings easily.
While it is possible to develop something akin to the allele
code system for the representation of unique GL Strings, a
more desirable solution would be to register each string with
a service that returns a unique Uniform Resource Identifier
(URI) (31) that can be easily dereferenced and with the
ability to return the string in multiple formats, as required by
the application requesting the information. Such a service is
currently under development. By eliminating the manual steps
required to curate allele codes, and by enlisting computational
resources for managing GL Strings, the management and
process issues associated with the NMDP allele code system
become moot.
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